The cross-border outlicensing activities of Chinese biotech firms reached a record transaction value of US$60 billion in the first quarter of 2026, driven by multinational pharmaceutical companies’ growing appetite for the country’s promising drug candidates. The deal value represented a 73 per cent jump from the same period a year earlier, and accounted for nearly half of the total US$135.7 billion worth of agreements signed throughout 2025, the National Medical Products Administration (NMPA) said in a statement on Saturday. The drug regulator did not reveal the number of transactions.

Full report : Deals reach US$60 billion in first quarter after analysts say Chinese biotech firms have shown substantial technological advancements.